KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Jazz Pharmaceuticals (JAZZ) Invested Capital (2016 - 2025)

Jazz Pharmaceuticals has reported Invested Capital over the past 16 years, most recently at $9.7 billion for Q4 2025.

  • Quarterly results put Invested Capital at $9.7 billion for Q4 2025, down 5.15% from a year ago — trailing twelve months through Dec 2025 was $9.7 billion (down 5.15% YoY), and the annual figure for FY2025 was $9.7 billion, down 5.15%.
  • Invested Capital for Q4 2025 was $9.7 billion at Jazz Pharmaceuticals, up from $9.3 billion in the prior quarter.
  • Over the last five years, Invested Capital for JAZZ hit a ceiling of $10.9 billion in Q2 2021 and a floor of $5.9 billion in Q1 2021.
  • Median Invested Capital over the past 5 years was $9.4 billion (2023), compared with a mean of $9.4 billion.
  • Biggest five-year swings in Invested Capital: surged 107.24% in 2021 and later dropped 17.08% in 2022.
  • Jazz Pharmaceuticals' Invested Capital stood at $10.0 billion in 2021, then dropped by 12.03% to $8.8 billion in 2022, then rose by 7.26% to $9.4 billion in 2023, then rose by 7.96% to $10.2 billion in 2024, then decreased by 5.15% to $9.7 billion in 2025.
  • The last three reported values for Invested Capital were $9.7 billion (Q4 2025), $9.3 billion (Q3 2025), and $9.1 billion (Q2 2025) per Business Quant data.